Antitumor Effect of Somatostatin Analogs in Neuroendocrine Tumors

被引：6
|
作者：
Chua, Yu Jo [1 ]
Michael, Michael [2 ]
Zalcberg, John R. [2 ]
Hicks, Rod J. [3 ]
Goldstein, David [4 ]
Liauw, Winston [5 ]
Price, Timothy [6 ]
机构：
[1] Canberra Hosp, Med Oncol Unit, Canberra, ACT, Australia
[2] Peter MacCallum Canc Ctr, Div Haematol & Med Oncol, Melbourne, Australia
[3] Peter MacCallum Canc Ctr, Ctr Mol Imaging, Melbourne, Australia
[4] Prince Wales Hosp, Dept Med Oncol, Randwick, NSW 2031, Australia
[5] St George Hosp, Canc Care Ctr, Kogarah, NSW, Australia
[6] Queen Elizabeth Hosp, Dept Oncol, Woodville, SA 5011, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 03期
关键词：
D O I：
10.1200/JCO.2009.26.0612
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E41 / E42
页数：2
相关论文
共 50 条
  • [41] Safety Review: Dose Optimization of Somatostatin Analogs in Patients with Acromegaly and Neuroendocrine Tumors
    Ludlam, William H.
    Anthony, Lowell
    ADVANCES IN THERAPY, 2011, 28 (10) : 825 - 841
  • [42] Resistance of neuroendocrine tumours to somatostatin analogs
    Angelousi, Anna
    Koumarianou, Anna
    Chatzellis, Eleftherios
    Kaltsas, Gregory
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2023, 18 (01) : 33 - 52
  • [43] Somatostatin Analogues in Neuroendocrine Tumors
    Kulke, Matthew H.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (03): : 241 - 242
  • [44] Somatostatin analogs or active surveillance in sporadic non-functioning pancreatic neuroendocrine tumors
    Maratta, M. G.
    Chiloiro, S.
    Raia, S.
    Maiorano, B. A.
    Horn, G.
    Brizi, M. G.
    Rufini, V.
    De Marinis, L.
    Bianchi, A.
    Schinzari, G.
    Inzani, F.
    Tortora, G.
    Rindi, G.
    ANNALS OF ONCOLOGY, 2023, 34 : S706 - S707
  • [45] Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study
    Brighi, Nicole
    Panzuto, Francesco
    Modica, Roberta
    Gelsomino, Fabio
    Albertelli, Manuela
    Pusceddu, Sara
    Massironi, Sara
    Lamberti, Giuseppe
    Rinzivillo, Maria
    Faggiano, Antongiulio
    Spallanzani, Andrea
    Ferone, Diego
    Prinzi, Natalie
    Rossi, Roberta Elisa
    Bruno, Annibale
    Colao, Anna Maria
    Campana, Davide
    ONCOLOGIST, 2020, 25 (03): : 259 - 265
  • [46] Prognostic significance of AKT/mTOR signaling in advanced neuroendocrine tumors treated with somatostatin analogs
    Fernandes, Isabel
    Pacheco, Teresa R.
    Costa, Adilia
    Santos, Ana C.
    Fernandes, Ana R.
    Santos, Mara
    Oliveira, Antonio G.
    Casimiro, Sandra
    Quintela, Antonio
    Fernandes, Afonso
    Ramos, Madalena
    Costa, Luis
    ONCOTARGETS AND THERAPY, 2012, 5 : 409 - 416
  • [47] Role of Interval Reduction of Somatostatin Analogs in Patients with Progressive Neuroendocrine Tumors: Our Experience
    Puliafito, I
    Prestifilippo, A.
    Colarossi, C.
    Giuffrida, P.
    Castorina, L.
    Blanco, G.
    Giuffrida, D.
    NEUROENDOCRINOLOGY, 2018, 106 : 204 - 204
  • [48] Somatostatin Analogs or Active Surveillance in Sporadic Non-Functioning Pancreatic Neuroendocrine Tumors
    Schinzari, G.
    Maiorano, B. A.
    Rossi, E.
    Bianchi, A.
    Chiloiro, S.
    Brizi, M. G.
    Rufini, V
    Inzani, F.
    De, Marinis L.
    Pontecorvi, A.
    Rindi, G.
    Tortora, G.
    NEUROENDOCRINOLOGY, 2020, 110 : 204 - 204
  • [49] Occurrence of exocrine pancreatic insufficiency in patients with advanced neuroendocrine tumors treated with somatostatin analogs
    Rinzivillo, Maria
    De Felice, Ilaria
    Magi, Ludovica
    Annibale, Bruno
    Panzuto, Francesco
    PANCREATOLOGY, 2020, 20 (05) : 875 - 879
  • [50] Report on the Clinicopathological Characteristics of 548 Romanian Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs
    Fica, S.
    Ghemigian, A.
    Ghervan, C.
    Croitoru, A.
    Pirvulescu, I
    Lambrescu, I. M.
    Martin, S.
    Poiana, C.
    NEUROENDOCRINOLOGY, 2017, 105 : 42 - 42
12345